Promotion H. Kuipers

Biliary tract cancer: Towards personalized treatment

Bile duct and gallbladder cancers (biliary tract cancer) have a poor prognosis and few treatment options. This thesis by Hendrien Kuipers explored two ways to improve care: extensive surgery for selected patients, and new drugs matched to a tumour’s genetic features. 

For bile duct cancer near the liver, the Mayo Clinic developed a liver transplant protocol combining strict patient selection with chemotherapy and radiation beforehand. Kuipers compared patients with and without this treatment. Survival was similar, but chemoradiation seemed to lower the risk of the cancer returning, though blood vessel complications were more common. The Dutch protocol now includes chemotherapy before transplantation.

For advanced gallbladder cancer, 33 Dutch patients who had major liver and/or pancreas surgery were studied. Complications were common, yet 30% lived at least two years. Those who did best had all cancer removed, with no spread into the liver or blood vessels. Another study showed that jaundice did not rule out long-term survival.

A review of almost 4,000 gallbladder tumours from 62 studies showed wide genetic variation. Some changes can be targeted by drugs approved for other cancers, so genetic testing could guide treatment.

Kuipers also tested two new drugs in laboratory and animal bile duct cancer studies. NXP900 blocks proteins that help cancer cells grow. It made chemotherapy work better and slowed tumours in mice carrying patients’ tumours. Adding a second drug made resistant cells respond again. NXP800 triggers a stress response that kills cancer cells and slowed tumour growth in mice. Based on these results, clinical trials have started.

Find the full thesis here: Biliary tract cancer: Towards personalized treatment